Xencor, Inc.

Genentech, Inc.

Juan Diaz

John R Desjarlais

Matthew J Bernett

Gregory L Moore

Rajat Varma

Michael Hedvat

Rumana Rashid

Veronica Gusti Zeng

Alex Nisthal

Suzanne Schubbert

Adam Zwolak

Ke Liu

Fei Shen

Matthew Adam Dragovich

Joseph Erhardt

Fouad Moussa

Theresa McDevitt

Pankaj Seth

Eric Chang

Christine Bonzon

Yoon Kyung Kim

Christine Huang

Patrick Holder

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains

Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Anti-CD28 x anti-PSMA antibodies

Provided herein are novel anti-CD28× anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28× anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3× anti-PSMA antibodies) for the treatment of prostate cancers.

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.

Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Untargeted and targeted IL-10 Fc-fusion proteins

The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties

Provided herein are novel anti-CD28×anti-B7H3 (also referred to as 'αCD28×αB7H3') heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

Anti-CD28 compositions

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains

Provided herein are novel anti-CD28&#xd7;anti-B7H3 (also referred to as '&#x3b1;CD28&#xd7;&#x3b1;B7H3') heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject &#x3b1;CD28&#xd7;&#x3b1;B7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.

Growing community of inventors

Anaheim Hills, CA, United States of America

Juan Diaz